Welcome to the December 2024 edition of the KRAS Patient Gateway newsletter—your place for the latest research and information about KRAS-positive lung cancer.
Since the approval of the first KRAS G12C targeted therapy in 2021, the field has continued to see rapid momentum as scientists work to improve current therapies and develop new ones for this most common form of KRAS mutation.
Currently, non-small cell lung cancer (NSCLC) with KRAS G12C mutations is typically treated with some form of immunotherapy as the first treatment option. If the cancer returns, two targeted therapy drugs, adagrasib and sotorasib, are available for patients.
Researchers are learning more about KRAS G12C targeted therapy. In data presented at the European Society for Medical Oncology (ESMO) 2024 conference in September, adagrasib improved outcomes for patients and worked better than standard chemotherapy, even in patients with brain metastases.
We are learning that the presence of certain additional co-mutations may predict how well patients will respond to treatment. Researchers are continuing to study the role of alterations in genes called STK11 and KEAP1 and how those predict potential treatment response.
Beyond the KRAS G12C mutation, researchers are also working hard to develop treatments for other KRAS G12X alterations (such as KRAS G12D).
For 40 years, researchers couldn’t get a handle on how to target KRAS-driven lung cancer. But they did it. And the field continues to progress, providing hope this holiday season.
Research News
Australia - Investing.com
Revolution Medicines reports promising trial results for cancer treatments
Published Dec 2, 2024
OncoDaily
Biagio Ricciuti: Discussing immunotherapy and targeted therapy for KRAS + NSCLC
Published Nov 27, 2024
Inside Precision Medicine
MD Anderson Researchers Identify NSCLC Patients Suited to Dual Immune Checkpoint Blockade
Published Oct 16, 2024
Oncology Nursing News
Adagrasib Boosts Outcomes in KRAS G12C-Mutated Lung Cancer
Published Sep 22, 2024
Open PR
How KRAS Inhibitors Are Transforming Cancer Therapy
Published Jul 26, 2024
FirstWord Pharma
Roche's divarasib to take on approved KRAS inhibitors in Phase III study
Published Jul 12, 2024
Get Connected
KRAS Virtual Meetups
Join us for the monthly KRAS group meetup on the third Wednesday of each month at 12 pm ET to meet and connect with others. Register today.
Lung Cancer Expert Videos Available Until December 31
You can still experience the International Lung Cancer Survivorship Conference (ILCSC) and hear from lung cancer experts. Free access to the recordings of this virtual education conference and Lung Cancer Basics Series is available until December 31. Register today
Have You Seen?
Celebrating 20 Years of Progress in Lung Cancer Research and Treatment
Watch the keynote address from the 2024 International Lung Cancer Survivorship Conference (ILCSC) highlighting the historical significance of uncovering lung cancer biomarkers and the development of a new class of drugs—targeted therapies—to target specific mutations in cells. Watch here
Brain Mets Basics for NSCLC
Learn all about brain metastases in non-small cell lung cancer with a section dedicated to treating brain mets in people with KRAS-positive lung cancer. Watch here
Understanding Clinical Trials: Three-Part Series
This series on clinical trials explains how drugs get approved by the FDA and become available to you.
Part 3: How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
…and there is always so much more to explore on the KRAS Patient Gateway.
If you were forwarded this email and you’d like to subscribe to this newsletter, you can sign up here.
If you need further assistance along your lung cancer journey, please email us at support@lungevity.org. Our team is always here to assist you.
